Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

NCT03504982 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Vericiguat (BAY1021189)
DRUG: Moxifloxacin
DRUG: Placebo

Sponsor

Bayer

Collaborators

[object Object]